资讯

AstraZeneca’s New Asthma Treatment Study Completes: Market Implications
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Targeted Oncology17 小时
BTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS
The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...
The Manila Times20 小时
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD ...
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 ...
ProMIS Neurosciences Inc.: ProMIS Neurosciences to Showcase Protein-Misfolding Drug ...
Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and ...